Probi Ab

Warszawski Uniwersytet Medyczny

Marek Aleksy Naruszewicz

Marie-Louise Johansson

Monika Ewa Czerwinska

Anna Karolina Kiss

Agnieszka Filipek

Magdalena Bujalska-Zadrozny

Hanna Bukowska

Magdalena Bujalska-Zad-Rozny

A description and explanation is provided of the use of oleacein, especially this obtained from., in the manufacturing of a preparation for the treatment and prevention of diseases that are consequences of the atherosclerotic plaque degradation. Such diseases include in particular those selected from the following group: ischemic brain stroke, heart attack and ischemic heart disease.

Oleacein for treating or preventing diseases resulting from atherosclerotic plaques

The disclosed analgesic pharmaceutical composition for oral administration is characterized in that it contains an opioid and a pharmaceutically admissible magnesium (II) compound, possibly along with one or more pharmaceutically admissible ancillary substances.

Analgesic pharmaceutical composition for oral administration

The invention refers to the use of a bacterial strain, preferably of the genus or , giving rise to increased amounts of propionic acid in the gut for the manufacture of a medicament for reduction of the level of oxidative stress factors, such as IL-6, reactive oxygen species (ROS), and adhesion molecules in mammals including man. The medicament can be used for the prophylaxis and/or treatment of chronic inflammatory diseases such as rheumatic diseases and psoriasis.

Reduction of oxidative stress factors with Lactobacillus plantarum

The invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level, and optionally cholesterol level, in blood. Said medicament can be utilized for the prophylaxis and/or treatment of circulatory diseases.

Growing community of inventors

Zalesie Gorne, Poland

Marek Aleksy Naruszewicz